Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardian Pharmacy Services, Inc. filings document the reporting obligations of a NYSE-listed long-term care pharmacy services company with Class A common stock. Recent Form 8-K filings furnish operating results, financial guidance, investor presentation materials, and exhibits tied to the company’s pharmacy services business.
Proxy and current-report filings also cover board elections, advisory compensation votes, stockholder voting results, material stock purchase agreements, lock-up arrangements, and conversion-related disclosures involving Class A and Class B common stock. These records describe governance, ownership, capital-structure mechanics, registered securities, and matters linked to the company’s September 2024 corporate reorganization.
Guardian Pharmacy Services, Inc. reported solid Q1 2026 growth, with revenue rising to $336.6M from $329.3M, a 2.2% increase. Net income grew to $13.5M from $9.3M, and diluted EPS rose to $0.21 from $0.15, reflecting margin expansion.
Cost of goods sold fell to $260.3M, or 77.3% of revenue, helped by lower product costs under the Inflation Reduction Act, lifting gross profit to $76.3M. Adjusted EBITDA increased to $29.8M, or 8.8% of revenue.
The company ended March 31, 2026 with $64.9M in cash and no borrowings under its $40M credit facility. It also converted 13.5M Class B shares into Class A and executed a Q1 2026 follow-on offering in which 1.02M Class A shares were sold and repurchased for cancellation without changing shares outstanding.
Guardian Pharmacy Services, Inc. reported stronger first quarter 2026 results, with higher profitability and raised guidance. Revenue for the quarter ended March 31, 2026 grew to $336.6 million from $329.3 million a year earlier, while net income attributable to the company increased to $13.3 million from $9.4 million. Adjusted EBITDA rose to $29.8 million, and net income and Adjusted EBITDA margins improved to 4.0% and 8.8%, respectively.
Management highlighted double-digit Adjusted EBITDA growth, 10% growth in residents served and prescription volumes, and stable margins despite pricing resets from the Inflation Reduction Act. Full-year 2026 revenue guidance remains $1.40–$1.42 billion, while Adjusted EBITDA guidance was raised to $123–$127 million, reflecting about $3 million of discrete IRA-related and payor benefits.
In March 2026, Guardian completed a non-dilutive secondary offering of 6.9 million Class A shares that increased public float and trading liquidity, with no proceeds retained and no change in total Class A shares outstanding. The company also filed a new shelf registration statement but states it currently has no plans to use it.
FMR LLC reported beneficial ownership of 2,359,356.71 shares of Class A Common Stock of Guardian Pharmacy Services Inc, representing 6.5% of the class as of 03/31/2026. The filing shows sole voting power of 2,357,526 shares and sole dispositive power of 2,359,356.71 shares. The report was signed under a power of attorney and references an Exhibit 99 and a 13d-1(k)(1) agreement.
Guardian Pharmacy Services, Inc. reported the initial holdings of Senior Vice President of Sales Richard Eakins. He directly holds 98,878 shares of Class A common stock and 36,052 shares of Class B common stock that automatically convert into Class A common stock on September 27, 2026 on a one-for-one basis.
He also holds a stock option for 25,000 shares of Class A common stock with a $32.59 exercise price that vests in full on March 13, 2029. Footnotes state his position also includes 5,063 and 4,476 restricted stock units that will settle in Class A shares upon vesting in 2028 and 2029.
Guardian Pharmacy Services, Inc. executive William Franklin Mudd, Senior Vice President of Finance, filed an initial statement of ownership as a reporting insider. He directly holds 98,465 shares of Class A common stock and 38,282 shares of Class B common stock that convert into Class A on September 27, 2026 on a one-for-one basis.
He also holds stock options covering 25,000 shares of Class A common stock with a $34.59 exercise price, vesting and becoming exercisable in full on February 11, 2029. In addition, his position includes 7,594 and 4,476 restricted stock units that vest on February 14, 2028 and March 1, 2029, respectively, each settling one-for-one in Class A shares.
Guardian Pharmacy Services, Inc. officer Douglas Towns reported his initial equity holdings. He directly holds 89,556 shares of Class A common stock and 23,450 shares of Class B common stock that automatically convert into Class A on a one-for-one basis on September 27, 2026. He also holds stock options covering 25,000 shares of Class A at an exercise price of $34.59 per share, vesting in full on February 11, 2029 and expiring in 2036, plus 7,594 and 4,476 restricted stock units scheduled to vest on February 14, 2028 and March 1, 2029, respectively.
Guardian Pharmacy Services, Inc. officer Martin David Norman filed an initial ownership report showing direct equity stakes in the company. He holds 101,040 shares of Class A common stock and Class B common stock convertible one-for-one into 39,865 Class A shares on September 27, 2026.
Norman also holds a stock option for 25,000 Class A shares at an exercise price of $34.59 per share, expiring in 2036 and scheduled to vest in full on February 11, 2029. Footnotes additionally describe 7,594 and 4,476 restricted stock units that will each settle one-for-one into Class A shares upon vesting in 2028 and 2029.
Guardian Pharmacy Services, Inc. executive Chris Crisafulli reports existing equity holdings in a Form 3 filing. The filing lists 55,469 shares of Class A common stock held directly and 18,931 shares of Class B common stock that convert into Class A on a one-for-one basis on September 27, 2026.
The report also discloses equity-based awards: 7,594 and 4,476 restricted stock units that vest on February 14, 2028 and March 1, 2029, respectively, settling in Class A shares, plus a stock option for 25,000 Class A shares at an exercise price of $34.59 per share that vests in full on February 11, 2029 and expires on February 11, 2036.
Guardian Pharmacy Services, Inc. officer Robert Weir reported his initial ownership of company equity. He directly holds 79,883 shares of Class A common stock and 23,450 shares of Class B common stock that automatically convert into Class A on September 27, 2026 on a one-for-one basis.
He also holds stock options covering 25,000 shares of Class A common stock with an exercise price of $34.59 per share, which vest and become exercisable in full on February 11, 2029. In addition, his position includes 5,063 and 4,476 restricted stock units that settle one-for-one into Class A shares upon full vesting on February 14, 2028 and March 1, 2029, respectively.
Guardian Pharmacy Services, Inc. (GRDN) executive Jeffrey Tuch has filed an initial ownership report showing his equity stake in the company. He directly holds 176,269 shares of Class A common stock and 55,578 shares of Class B common stock that automatically convert into Class A on September 27, 2026. He also holds stock options for 25,000 Class A shares at an exercise price of $34.59 per share, expiring on February 11, 2036, which vest on February 11, 2029. In addition, his position includes 5,063 and 4,476 restricted stock units that vest on February 14, 2028 and March 1, 2029, respectively, each settling one-for-one in Class A shares.